Loading
A phase 2 trial of Fianlimab, Cemiplimab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery is a phase 2 interventional study registered as NCT06161441 by Regeneron Pharmaceuticals, with 195 participants enrolled, started 2024-07-16 and due to reach its primary completion in 2026-08-24. Interventions recorded: Fianlimab, Cemiplimab, Pemetrexed, Paclitaxel, Carboplatin. Conditions listed: Resectable Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Fianlimab, Regeneron, Cemiplimab, Pemetrexed.
Shares Fianlimab, Regeneron, Cemiplimab, Small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.